Lannett Reports the Completion of Patient Dosing in Pivotal Clinical Trial for Biosimilar Insulin Glargine
Shots:
- The company has completed the patient dosing in the PK and PD study of biosimilar insulin glargine in the healthy volunteer. The biosimilar is being co-developed with its strategic alliance partners within HEC
- Additonally, no serious AEs were reported & the further results are expected to be available at the end of 2022
- The company will file the BLA for a biosimilar and interchangeable insulin glargine to Sanofi's Lantus Solostar in 2023 & the product is expected to be available in H1’24
Ref: PR Newswire | Image: LANNETT
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
